GLP1R and type 2 diabetes mellitus: Similarly, amongst patients with CP and T2DM, GLP-1 RA use was associated with a lower 5-year incidence of pancreatic cancer (HR 0.53, 95% CI 0.31-0.91, <i>p</i> < 0.05).